belimumab, Benlysta

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

View Luspus Slideshow Pictures

GENERIC NAME: belimumab

BRAND NAME: Benlysta

DRUG CLASS AND MECHANISM: Belimumab is a synthetic (man-made) injectable antibody that reduces the activity of immune cells called B-cells in patients with systemic lupus erythematosus (SLE). SLE is an inflammatory autoimmune disease, which means that the body's immune system attacks its own tissues and causes inflammation. Parts of the body affected by SLE include the heart, skin, joints, kidneys, lungs, and brain. Common symptoms include rash, fever, chest pain, hair loss, joint pain, fatigue, and sensitivity to light.

One type of immune cell that is involved in the immune attack in SLE is the B-cell. One of the functions of B-cells is to produce antibodies, proteins that the body usually produces to fight infection. The B-cells in SLE produce antibodies that may be involved in the autoimmune attack in SLE. Belimumab blocks the action of B-cell (lymphocyte) stimulator (BLyS) protein, which B-cells require for survival. By blocking BLys, belimumab reduces the number of B-cells available to produce antibodies that contribute to SLE. In clinical studies, belimumab-treated patients experienced less activity of their SLE than those who received other SLE therapies. Belimumab was approved by the FDA in March 2011.

PRESCRIBED FOR: Belimumab is used for the treatment of adults with active, antibody-positive SLE who are receiving other treatments for SLE. It has not been evaluated in patients with severe active inflammation of the kidney (nephritis) or the central nervous system (brain and spinal chord).

Medically Reviewed by a Doctor on 6/17/2015

Quick GuideLupus Symptoms, Rash, and Treatment

Lupus Symptoms, Rash, and Treatment
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

See more info: belimumab on RxList
RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Newsletters

Get the latest health and medical information delivered direct to your inbox!

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors